KKR Soars 4.14% on Biotage Acquisition, Credit Funds Launch

On May 1, 2025, KKR's stock surged by 4.14% in pre-market trading, reflecting a strong start to the day's trading session.

KKR's recent acquisition of the Swedish life sciences company Biotage for $12.2 billion has been a significant move, showcasing the company's aggressive expansion strategy in the healthcare sector. This acquisition is part of a broader trend of substantial investments in the life sciences industry, which has seen a total investment of over 100 billion yuan in recent weeks.

In addition to its acquisition activities, KKR has also made strategic moves in the credit market. The company, in partnership with Capital Group, has launched two new interval funds focused on credit strategies. These funds, named Capital Group KKR Core Plus+ and Capital Group KKR Multi-Sector+, are designed to bridge the gap between public and private investments, offering individual investors a way to diversify their portfolios with exposure to credit markets. This initiative underscores KKR's commitment to expanding its investment offerings and catering to a broader range of investors.